USC Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, California.
Center for Precision Medicine, City of Hope National Medical Center and Beckman Research Institute, Duarte, California.
Cancer. 2021 Apr 15;127(8):1275-1285. doi: 10.1002/cncr.33357. Epub 2020 Dec 15.
Little is known about the psychological outcomes of germline multigene panel testing, particularly among diverse patients and those with moderate-risk pathogenic variants (PVs).
Study participants (N = 1264) were counseled and tested with a 25- or 28-gene panel and completed a 3-month postresult survey including the Multidimensional Impact of Cancer Risk Assessment (MICRA).
The mean age was 52 years, 80% were female, and 70% had cancer; 45% were non-Hispanic White, 37% were Hispanic, 10% were Asian, 3% were Black, and 5% had another race/ethnicity. Approximately 28% had a high school education or less, and 23% were non-English-speaking. The genetic test results were as follows: 7% had a high-risk PV, 6% had a moderate-risk PV, 35% had a variant of uncertain significance (VUS), and 52% were negative. Most participants (92%) had a total MICRA score ≤ 38, which corresponded to a mean response of "never," "rarely," or only "sometimes" reacting negatively to results. A multivariate analysis found that mean total MICRA scores were significantly higher (more uncertainty/distress) among high- and moderate-risk PV carriers (29.7 and 24.8, respectively) than those with a VUS or negative results (17.4 and 16.1, respectively). Having cancer or less education was associated with a significantly higher total MICRA score; race/ethnicity was not associated with the total MICRA score. High- and moderate-risk PV carriers did not differ significantly from one another in the total MICRA score, uncertainty, distress, or positive experiences.
In a diverse population undergoing genetic counseling and multigene panel testing for hereditary cancer risk, the psychological response corresponded to test results and showed low distress and uncertainty. Further studies are needed to assess patient understanding and subsequent cancer screening among patients from diverse backgrounds.
Multigene panel tests for hereditary cancer have become widespread despite concerns about adverse psychological reactions among carriers of moderate-risk pathogenic variants (mutations) and among carriers of variants of uncertain significance. This large study of an ethnically and economically diverse cohort of patients undergoing panel testing found that 92% "never," "rarely," or only "sometimes" reacted negatively to results. Somewhat higher uncertainty and distress were identified among carriers of high- and moderate-risk pathogenic variants, and lower levels were identified among those with a variant of uncertain significance or a negative result. Although the psychological response corresponded to risk, reactions to testing were favorable, regardless of results.
关于种系多基因panel 检测的心理结果,我们知之甚少,尤其是在不同的患者和具有中度风险致病性变异(PVs)的患者中。
研究参与者(N=1264)接受了 25 或 28 基因panel 的咨询和检测,并在 3 个月的postresult 调查中完成了多维癌症风险评估(MICRA)。
平均年龄为 52 岁,80%为女性,70%患有癌症;45%为非西班牙裔白人,37%为西班牙裔,10%为亚洲人,3%为黑人,5%为其他种族/民族。约 28%的人接受过高中教育或以下教育,23%的人不讲英语。基因检测结果如下:7%有高危 PV,6%有中危 PV,35%有意义未明的变异(VUS),52%为阴性。大多数参与者(92%)的总 MICRA 评分≤38,这对应于一种平均反应为“从不”、“很少”或仅“有时”对结果产生负面反应。多变量分析发现,高风险和中度风险 PV 携带者的平均总 MICRA 评分显著更高(分别为 29.7 和 24.8),而 VUS 或阴性结果携带者的评分则较低(分别为 17.4 和 16.1)。患有癌症或受教育程度较低与总 MICRA 评分显著相关;种族/民族与总 MICRA 评分无关。高风险和中度风险 PV 携带者的总 MICRA 评分、不确定性、苦恼或阳性体验无显著差异。
在接受遗传性癌症风险基因咨询和多基因 panel 检测的不同人群中,心理反应与检测结果相对应,表现出低水平的苦恼和不确定性。需要进一步研究以评估不同背景患者的患者理解和随后的癌症筛查。
患者人群接受panel 检测发现,92%“从不”、“很少”或仅“有时”对结果产生负面反应。在高风险和中度风险致病性变异携带者中,确定了较高的不确定性和苦恼,而在具有意义未明的变异或阴性结果的携带者中,确定了较低的不确定性和苦恼。尽管心理反应与风险相对应,但无论结果如何,检测反应均为有利。